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Abstract
Serine proteases play a crucial role in host-pathogen interactions. In the innate immune system of invertebrates, multi-
domain protease inhibitors are important for the regulation of host-pathogen interactions and antimicrobial activities.
Serine protease inhibitors, 9.3-kDa CrSPI isoforms 1 and 2, have been identified from the hepatopancreas of the horseshoe
crab, Carcinoscorpius rotundicauda. The CrSPIs were biochemically active, especially CrSPI-1, which potently inhibited
subtilisin (Ki=1.43 nM). CrSPI has been grouped with the non-classical Kazal-type inhibitors due to its unusual cysteine
distribution. Here we report the crystal structure of CrSPI-1 in complex with subtilisin at 2.6 A ˚ resolution and the results of
biophysical interaction studies. The CrSPI-1 molecule has two domains arranged in an extended conformation. These two
domains act as heads that independently interact with two separate subtilisin molecules, resulting in the inhibition of
subtilisin activity at a ratio of 1:2 (inhibitor to protease). Each subtilisin molecule interacts with the reactive site loop from
each domain of CrSPI-1 through a standard canonical binding mode and forms a single ternary complex. In addition, we
propose the substrate preferences of each domain of CrSPI-1. Domain 2 is specific towards the bacterial protease subtilisin,
while domain 1 is likely to interact with the host protease, Furin. Elucidation of the structure of the CrSPI-1: subtilisin (1:2)
ternary complex increases our understanding of host-pathogen interactions in the innate immune system at the molecular
level and provides new strategies for immunomodulation.
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Introduction
Serine proteases play an important immunomodulatory role
in host-pathogen interactions. Invertebrates lack an adaptive
immune system that recognizes and remembers specific
pathogens [1]. As an evolutionarily conserved and ancient
d e f e n s es t r a t e g y ,t h ei n n a t ei m m u ne system responds instanta-
neously to invading pathogens in a non-specific manner. The
innate immune system in the horseshoe crab, Carcinoscorpius
rotundicauda, comprises serine protease cascades that are similar
to the blood coagulation, melanization and complement systems
[2]. Horseshoe crab hemocytes contain granules filled with
several serine protease zymogens. Upon mechanical injury or
pathogen invasion, the granules are released into the extracel-
lular milieu by exocytosis. Furthermore, clotting enzymes, in
their precursor forms, are activated by a serine protease cascade
that is triggered by bacterial endotoxins [3,4]. Several serine
protease zymogens, including proclotting enzymes, Factor B and
Factor C, are associated with the hemolymph coagulation
system. The subsequent formation of the coagulation plug
prevents further entry of pathogens [5,6].
In parallel, a large number of protease inhibitors are also
expressed in hemocytes with varying specificities, which target the
proteases of different microorganisms [7], including the serine
proteases like elastase, subtilisin and protease K. These inhibitors
belong mainly to the Kazal, Kunitz and a2-macroglobulin families
and they use a lock-and-key mechanism with their reactive site
loops to mechanistically bind the active sites of the target proteases
[8]. It has been speculated that these inhibitors might participate
in the regulation of the hemolymph coagulation cascade [9,10].
During our recent work on subtractive ESTs (expressed sequence
tags) from the Carcinoscorpius rotundicauda that was infected with
Pseudomonas aeruginosa, two isoforms of the non-classical Kazal-type
inhibitor, CrSPI, each of 9.3 kDa, were discovered [9]. The
CrSPI-1 and CrSPI-2 (GenBank Accession numbers DQ090491
and DQ090492, respectively) isoforms share 97% sequence
identity. Both isoforms are biochemically active. In our earlier
study [9], we have tested representative microbial serine proteases
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serine protease, trypsin. While trypsin was inhibited only by
CrSPI-2, subtilisin was found to be most susceptible for inhibition
by CrSPI-1, with Ki of 1.4610
29 M. Hence subtilisin was used to
maximize the exploration of the activity of CrSPI-1. Moreover
subtilisin is secreted in large amounts by many bacillus species like
Bacillus subtilis. B. subtilis thrives in the natural habitat (estuarine
muddy swamp) of the horseshoe crab (C. rotundicauda), although
there is no report that B. subtilis is a pathogen of C. rotundicauda.
Serine protease inhibitors in the plasma have been known to
perform dual functions: (i) regulation of the activity of endogenous
serine proteases and (ii) inhibition of microbial serine proteases as
a host immune defense against invading pathogens [11]. For
instance, the human lympho-epithelial Kazal-type inhibitor
(LEKTI) plays an important role in epithelial tissue homeostasis
through the regulation of trypsin, and dysfunction of LEKTI has
been implicated in Netherton syndrome [12]. Furthermore, the
Limulus serpins, LICI-1, LICI-2 and LICI-3, from the horseshoe
crab are known to regulate serine proteases in the pathogen-
induced coagulation cascade [13]. CrSPI may possibly downreg-
ulate the blood coagulation serine enzymes, especially in view of
helping the host to avoid random activation of coagulation under
normal conditions. However, this remains a speculation until
future tests are carried out.
The Kazal family is 1 of 18 families of serine protease inhibitors.
Since the 19809s, the structures of several members of this family
have been reported [14]. The Kazal family is mainly divided into
two groups: the classical and the non-classical inhibitors [15]. The
positions of the cysteine residues that form disulfide bonds differ
among the classical and non-classical Kazal-type inhibitors [16].
The classical group is best represented by the pancreatic secretory
trypsin inhibitor and the ovomucoids. Furthermore, the non-
classical Kazal inhibitors are divided into group I and group II.
The characteristic feature of group I inhibitors is that the disulfide
bond between the first and fifth cysteine residues is shifted towards
the C-terminus compared to the respective residues of a classical
Kazal inhibitor, like OMTKY3.
Both domains 1 and 2 of CrSPI-1 share sequence homology
with the non-classical group I Kazal-type inhibitors. Other
representatives of the non-classical group I Kazal-type inhibitors
are the Anemonia elastase inhibitor, Crayfish inhibitor [17], Ciona
trypsin inhibitor [18] and Galleria trypsin inhibitor [19]. The non-
classical group II inhibitors have a cystine-stabilized a-helical
motif (CSH motif) composed of an a-helix that spans the Cys-X1-
X2-X3-Cys portion and is cross-linked by two disulfide bridges.
Representatives of this group are the Leech Derived Trypsin
inhibitor (LDTI-C) [20], Bdellin B-3 from the leech Hirudo nipponia
[21], Rhodniin from the blood-sucking insect Rhodnius prolixus [22],
the thrombin inhibitor Dipetalogastin from the bloodsucking
insect Dipetalogaster maximus and Ascidian Trypsin Inhibitor [23]
from the sea squirt.
Although several structures have been reported for Kazal-type
inhibitors, a structure has not been reported for a protease inhibitor
from the hemolymph of an ancient arthropod. The horseshoe crab
has been dubbed a ‘‘living fossil’’ with several hundred million years
of evolutionary success, indicating that it harbors a formidable
antimicrobial system. Therefore, it is conceivable that the CrSPI
from the Carcinoscorpius rotundicauda, which thrives in microbiolog-
ically-challenging habitat, would exhibit unique antimicrobial
properties. Moreover, there are no crystal structures available for
a non-classical group I Kazal-type inhibitor, except for the solution
structure of the Anemonia elastase inhibitor from the sea anemone
[15]. Here, we report the crystal structure of the two-headed non-
classical Kazal-type group I inhibitor CrSPI-1 in complex with its
cognate protease, subtilisin, at a stoichiometric ratio of 1:2 (CrSPI-1
to subtilisin) and refined up to 2.6 A ˚ resolution. The reactive site
loops of both domains of CrSPI-1 occupy the substrate binding
pockets of subtilisin. Furthermore, based on our structural and
biophysical interaction studies, we propose that domain 2 of CrSPI-
1 is a more specific and potent inhibitor of subtilisin, whereas
domain 1 likely interacts with CrFurin (Carcinoscorpius rotundicauda
Furin), a subtilisin homolog of the host that belongs to the family of
Furins or kexins, which are known to be involved in the processing
of protein precursors, including many immune proproteins [24].
Earlier, we have proposed that CrSPI-1 may act as an ‘‘on-off’’
regulatory switch in the modulation of antimicrobial activities while
maintaining homeostasis of host proteases [9]. Our present findings
provide a new structural insightintohost-pathogen interaction. Our
delineation of the bioactive sites of the two domains of CrSPI-1,
which could differentiate between the bacterial and host proteases,
might provide an impetus for the development of new strategies for
novel antimicrobial drugs and immunomodulators.
Methods
Expression, purification, crystallization and data
collection
The CrSPI-1 gene was cloned and expressed in E. coli with the
pET32-EkLIC system (Novagen) using the following primers:
Forward 59 ACG GAC GAC GAC AAG ATG TGT CCT CAT
ACT TAC AAA 39 and Reverse 59 ACG GAG GAG AAG CCC
GGT TTA CAA GCA AGC TTC TAG TGG 39 [25]. The
expressed protein contained a thioredoxin tag, a His-tag and an
enterokinase cleavage site. The recombinant CrSPI-1 was overex-
pressed at 37uC from a single colony picked from an agar plate. The
culture was induced with 300 mM isopropyl 1-thio-D-galactopyr-
anoside for 4 h to an OD600nm of 0.6. Cells were then harvested by
centrifugation (9000 g, 20 min, 4uC) and sonicated. The protein
was purified using Nickel-NTA affinity beads (Qiagen) with
Phosphate Buffered Saline (PBS) at pH 7.4 and 10 mM b-
mercaptoethanol (2BME). The protein was eluted in 300 mM
imidazole. The thioredoxin tag was cleaved through a 2-h
incubation with enterokinase (Sigma). The complex was prepared
by mixing CrSPI-1 with subtilisin Carlsberg obtained from Bacillus
licheniformis, (Sigma) in an approximate molar ratio of 1:2 (inhibitor
to enzyme) and incubated for 1 h at 37uC. The complex was
purified using a Superdex-75 gel filtration column, and fractions
were pooled and concentrated up to 20 mg/ml. Crystallization
screens were performed using the hanging drop vapor diffusion
method with Hampton Research Crystal Screen kits I and II and JB
Screens (Jena BioScience, Germany) at room temperature. The
initial crystallization conditions were further optimized using a grid
screen by varying the concentration of the precipitant. Plate-like
diffraction quality crystals were obtained from 11% (w/v)
Polyethylene Glycol 20000 in 0.1 M 2-(N-morpholino) ethanesul-
fonic acid (MES) at pH 6.5. The crystallization solution was
supplemented with 25% glycerol, which acts as a cryo-protectant. A
complete dataset was collected in the X29-A synchrotron beamline
at Brookhaven National Laboratories, USA. The data collection
and refinement statistics are provided in Table 1.
Structure solution and refinement
The structure of the recombinant CrSPI-1: subtilisin complex
was solved by the molecular replacement method with Molrep
[26] using the subtilisin Carlsberg coordinates (PDB code 1SCA).
The initial R-factor was 47% and subsequent refinement was
performed with Refmac [27] and CNS [28]. Non-crystallographic
symmetry (NCS) restraints were used for subtilisin molecules
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40, the calculated electron density map allowed us to build the
CrSPI-1 molecule. Several cycles of refinement in CNS with
alternating model building for the inhibitor complex was carried
out using the programs O [29] and Coot [30]. It was noticed that
the B-factors of CrSPI-1 molecule is higher, might indicate its
reduced occupancy; however, it is well defined in the electron
density map (Figure 4C). The overall geometry of the final model
was analyzed by MolProbity [31] which showed 93.9% of the
residues in the favored region and no residue in the disallowed
region (Table 1).
Isothermal Titration Calorimetry (ITC)
ITC studies were performed using the MicroCal VP-ITC and
MicroCal ITC-200 instruments. CrSPI-1 at a concentration of
0.2 mM in PBS at pH 7.4 and 10 mM BME, was titrated into a
solution of 0.012 mM subtilisin in PBS at pH 7.4 and 10 mM
BME in the sample cell with injections of 2 mL (ITC-200) or 10 mL
(VP-ITC). Additionally, the VCTEEY peptide, at a concentration
of 11 mM in PBS at pH 7.4 and 10 mM BME, was titrated into a
0.063 mM subtilisin solution in PBS at pH 7.4 and 10 mM BME
in the sample cell with injections of 1 mL. This peptide was
designed based on the reactive site loop sequence of CrSPI-1 that
is in the proximity of the active site of subtilisin in the CrSPI-1:
subtilisin complex in the crystal structure. The VCTEEY peptide,
which contains the RSL residues from P4 to P29 of CrSPI-1
domain 2, was purchased from Sigma-Aldrich. All experiments
were performed at 37uC. Samples were degassed prior to use. Due
to dilution across the needle during equilibration, the initial peak
was discarded. Data analysis was performed using the MicroCal
Origin software. For the rCrSPI-1 experiments, a model
considering an interaction with a binding stoichiometric ratio of
1:2 CrSPI-1: subtilisin (CrSPI-1, the macromolecule with two
binding sites for subtilisin is located in the syringe) in terms of the
overall association constants or the site-specific intrinsic micro-
scopic association constants was employed [32,33], whereas for the
VCTEEY peptide binding experiments, a model considering a
stoichiometric ratio of 1:1 VCTEEY peptide to subtilisin was
employed. Experiments were performed in duplicate. Typical
errors were 15–20% for the association constant and 5–10% for
the binding enthalpy.
Results
The structure of recombinant CrSPI-1 in complex with
subtilisin was solved by the molecular replacement method from
a synchrotron dataset. The model was refined to a final R-factor of
0.21 (Rfree=0.24) at 2.6 A ˚ resolution with good stereochemical
parameters (Table 1). The final refined model consisted of residues
from Cys1 to Val73 of CrSPI-1 and Ala1 to Gln274 of subtilisin.
Eight residues (Val74-Glu81) at the C-terminus of CrSPI-1 lacked
interpretable electron density and were not modeled. There were
three subtilisin molecules and one CrSPI-1 molecule in the
asymmetric unit. Each CrSPI-1 molecule interacted with two
subtilisin molecules, i.e., domain 1 and domain 2 of CrSPI-1
interacted with two independent subtilisin molecules (Fig. 1). The
third subtilisin molecule of the asymmetric unit was not in a
complex with CrSPI-1. This indicates that free subtilisin molecules
were present in the crystallization drop due to the lack of adequate
inhibitor molecules.
The conformation of the subtilisin molecules in the complex was
similar to that seen in the subtilisin Carlsberg (EC 3.4.21.62)
structure and structures of subtilisin complexed with small ligands
[34–36]. The structure consists of a central seven-stranded parallel
b-sheet with two a-helices on one side and a group of four a-
helices on the other side of the central b-sheet. The catalytic triad,
which consists of Ser220, His64 and Asp32, was located in the
substrate-binding cleft. The three subtilisin molecules of the
asymmetric unit were identical with an rmsd of 0.1 A ˚ in a pairwise
superimposition of 274 Ca atoms. This indicates that there was no
significant conformational change of subtilisin molecules upon
complex formation with the CrSPI-1 molecule.
Structure of CrSPI-1
The CrSPI-1 molecule comprises two domains: domain 1 from
Cys1 to Glu40 and domain 2 from Leu41 to Leu83. Both domains
adopted similar secondary structures (domain 1 b1 q b2 Q a1b3 q and
domain 2 b4 q b5 Q a2). The presence of a central a-helix, a1 (Glu18–
Ala24) in domain 1 and a2 (Arg63-Ser68) in domain 2, and an
antiparallel b-sheet in each domain are characteristic of the classical
Table 1. Crystallographic data and refinement statistics.
Data collection
#
Unit cell parameters(A ˚, u) a=73.8, b=65.1, c=111.9
a=90,b=95.44, c=90
Space group P21
Resolution range (A ˚) 50-2.6 (2.64-2.60)
Wavelength (A ˚) 0.9600
Observed hkl 205529
Unique hkl 32884
Completeness (%) 99.8 (99.3)
Redundancy 6.3 (5.3)
Overall I/sI 7.2 (3.3)
aRsym (%)
" 10 (34)
Refinement and quality of model
*Resolution range (A ˚) 15-2.6
bRwork (no. reflections) 0.21 (24818)
cRfree (no. reflections) 0.24 (1533)
Root mean square deviation
Bond length (A ˚) 0.009
Bond angle (u) 1.52
Ramachandran plot
Favored region (%) 93.9
Allowed regions (%) 5.0
Generously allowed region (%) 1.1
Disallowed regions (%) 0.0
dAverage B-factors (A ˚2)
CrSPI-1 (no. of atoms) 57.2(514)
Subtilisin (no. of atoms) 32.4(5760)
Overall protein atoms (no. of atoms) 37.4 (6274)









i Iih ðÞwhere Ii(h) and I(h) are the i
th and mean





h Fo, where Fo and Fc are the observed and calculated
structure factor amplitudes of reflection h.
cRfree =a sf o rR work, but approximately 8% of the total reflections chosen at
random and omitted from refinement.
dIndividual B-factor refinement were carried out.
*Reflections greater than I.sI where used in the refinement.
#Values in the parentheses are corresponding to the highest resolution shell.
"Indicates the moderate quality of data.
doi:10.1371/journal.pone.0018838.t001
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non-classical Kazal-type serine protease inhibitor in that it harbored
an unusual pattern of conserved cysteines. There were two intra-
domain disulfide bridges in domain 1 (Cys1-Cys19 and Cys8-Cys35)
and three in domain 2 (Cys41-Cys70, Cys45-Cys64 and Cys53-
Cys82) (Fig. 1A). Using a BLAST search, the sequence identity
between CrSPI-1 and the most homologous member of the Kazal
family of inhibitors was analyzed. The observed pattern of S-S
bridges in CrSPI-1 was more similar to the non-classical Kazal-type
group 1 inhibitors from sea anemone and crayfish than to the
mammalian and avian inhibitors (Figs. 2 and S2).
A search for topologically similar proteins within the PDB
database was performed with the DALI program [37]. There were
no structural homologs of full-length CrSPI-1; however, the DALI
search with individual domains showed similarity with several
Kazal-type inhibitors. The DALI search with domain 1 (residues
Cys1-Glu40) against the pdb database showed that it was
structurally similar to leech-derived tryptase inhibitor (pdb code
1ldt) with an rmsd of 2.0 A ˚ for 38 Ca atoms (30% sequence
identity). This was followed by dipetalin, a Kazal-type thrombin
inhibitor (rmsd=2.0 A ˚ for 37 Ca atoms; 27.5% identity; pdb code
1kma) and an insect-derived double domain Kazal inhibitor,
rhodniin, which is a highly specific thrombin inhibitor
(rmsd=1.5 A ˚ for 36 Ca atoms; 35% identity; pdb code 1tbq).
Similarly, the structural homology search with domain 2 (Leu41-
Leu83) showed several matches with Kazal-type inhibitors.
Domain 2 is structurally homologous to turkey ovomucoid third
domain (OMTKY3), a subtilisin inhibitor (pdb code 1yu6), with
an rmsd of 2.3 A ˚ for 32 Ca atoms with 25% sequence identity.
This was followed by the thrombin inhibitor rhodniin
(rmsd=2.3 A ˚ for 31 Ca atoms; 7.5% identity; pdb code 1tbq)
and leech-derived tryptase inhibitor (pdb code 1an1), which has an
rmsd of 2.4 A ˚ for 29 Ca atoms with 20% sequence identity. Most
of the structurally characterized Kazal-type inhibitors contain a
single domain, except for rhodniin. Rhodniin is the only
structurally characterized Kazal-type inhibitor with two domains
in complex with thrombin (1:1 ratio). Both CrSPI-1 domains show
significant structural similarity to the respective domains of
rhodniin. However, full-length CrSPI-1 could not be superim-
posed with full-length rhodniin. This indicates that the relative
orientations of the two domains are different. Notably, Rhodniin
binds with only a single serine protease (thrombin) whereas CrSPI-
1 binds with two serine protease molecules. This might be due to
the variations of the reactive site loop residues at the prime side of
the substrate binding site, which might dictate the specificity of
these inhibitors towards a particular serine protease.
The comparison of CrSPI-1 domains 1 and 2 revealed that the
core regions superimposed with an rmsd of 3.9 A ˚ for 24 Ca atoms
(Fig. 3). The sequence alignment showed 27% identical (42%
similar) residues between the two domains, including the highly
conserved cysteines (Fig. 2). The highly conserved S-S bridges
probably maintain the architecture of these domains. The overall
fold similarity between these two domains, together with the
structural homology with other Kazal-type inhibitors, suggests that
Figure 1. Structure of the CrSPI-(subtilisin)2 complex. (A) Shows the Ca trace of CrSPI-1. The disulphide bonds are shown in thick lines along
with the residue numbers. Domain-1 is in magenta and domain-2 is in yellow color. The approximate location of the missing residues (residues 74 to
81) is shown as dotted line. The P1 residues His3 and Glu48 of both domains are shown. (B) Ribbon representation of subtilisin molecules are drawn
in blue and green color and two domains of rCrSPI are in magenta and yellow color. (C) Shows the CrSPI-1: subtilisin complex. CrSPI-1 is in ribbon
representation and subtilisin is in surface representation. These figures were prepared by using PyMol [54] and Molscript [55].
doi:10.1371/journal.pone.0018838.g001
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via duplication while maintaining divergent amino acid sequences.
A study by Merckel et al. [38] showed that the similarities between
the tertiary structures are indicators of gene duplication.
CrSPI-1: subtilisin complex
The CrSPI-1: subtilisin complex is a heterotrimer in solution,
which was confirmed by gel filtration, non-reducing SDS-PAGE
[25] and Isothermal Titration Calorimetry (ITC) experiments (Fig.
S3). This is consistent with the observation of a heterotrimer of a
1:2 ratio of CrSPI-1 to subtilisin in the asymmetric unit of the
crystal (Fig. 1). Both domains of CrSPI-1 act as heads that bind
with two individual subtilisin molecules. Our earlier work showed
that domain 1 alone did not react with subtilisin, whereas domain
2 showed high affinity for subtilisin with a Ki of 2.6 nM [9].
However, the structural studies revealed that although both
domains indeed bind to subtilisin, only domain 2 showed tight
interactions with subtilisin. We hypothesize some possible reasons
for the tighter interaction of domain 2 in the section ‘‘Rigidity of
the RSL.’’ The two subtilisin molecules were bound at the
opposite ends of the elongated inhibitor molecule and formed a
ternary complex. Subtilisin is a monomer in solution; upon
formation of a complex with rCrSPI, it becomes a heterotrimer.
Rhodniin, a two domain non-classical group II Kazal-type
inhibitor from the blood sucking insect Rhodnius prolixus, was
shown to inhibit thrombin at a 1:1 ratio by binding of one domain
at the active site and the other domain at the exosite [39].
Similarly, the crystal structure of an inhibitor belonging to the
potato II inhibitor family, a completely different family of serine
protease inhibitors, showed that the two-headed Tomato Inhib-
itor-II inhibits two subtilisin molecules with a Ki of 9 nM [40].
More recently, a two-headed arrowhead protease inhibitor, which
belongs to the Kunitz family of protease inhibitors in a complex
with two trypsin molecules, was reported [41]. The present study
on the CrSPI-1: subtilisin heterotrimer complex is the first of the
non-classical Kazal-type inhibitors that employs a dual-inhibition
mechanism to engage two protease molecules with different
specificities.
CrSPI-1 reactive site loop interactions with subtilisin
The reactive site loop (RSL) of domain 1 of CrSPI-1 (Cys1 to
Lys6) binds at the active site region of subtilisin from P3 (Cys1) to
P39 (Lys6) in a substrate-like manner (Fig. 4A, panel 1). There
were 11 hydrogen bonding contacts between the domain 1 RSL
and subtilisin. Of these, five hydrogen bonding contacts were
mediated by side chains. The main chain amide group of the P1
residue His3 was involved in a hydrogen bonding contact with O
c
of the catalytic Ser220 (2.63 A ˚). The carbonyl O atom of the P1
Figure 3. Stereo view of the Ca superimposition of domain-1 (magenta) and domain-2 (yellow) of CrSPI-1. These two domains
superimpose with an rmsd of 3.9 A ˚ for 24 Ca atoms. The superimposition was carried out using DALI [37]. This figure was prepared by using PyMol
[54].
doi:10.1371/journal.pone.0018838.g003
Figure 2. Multiple sequence alignment for the representative members of Kazal-type Non classical group I proteinase inhibitors-
Ciona trypsin inhibitor, crayfish inhibitor, Anemonia elastase inhibitor, CrSPI-1 domain 1 and CrSPI-1 domain 2. Secondary structural
elements are shown above the sequences. Conserved residues are shaded in red and yellow boxes. The reactive site loop residues of P4-P29 are
represented in a green box. The reactive site residue P1 is shown using an upward pointing magenta arrow. This figure was prepared by the program
Espript [56].
doi:10.1371/journal.pone.0018838.g002
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Ser220 and N
c2 of Asn154 of subtilisin (Table S1). In Kazal-type
inhibitor complexes, the P1 residue alone makes approximately
50% of the hydrogen bonding interactions with the active site
residues [42,43]. In the CrSPI-1: subtilisin complex, the P1 residue
His3 of the CrSPI-domain 1 contributes 5 hydrogen bonding
contacts (or 45% of the total hydrogen bonding interactions) with
subtilisin. Pro2 occupies the P2 position and makes hydrophobic
interactions with subtilisin. In most of the canonical serine
proteinase inhibitors, the P3 residue is engaged in a disulfide
bond. In CrSPI-1, Cys1 is in the P3 position and engaged in a
disulfide bond with Cys19, which is part of the hydrophobic core
that consists of Leu125 (subtilisin) and Pro2 (CrSPI). Thr4 is in the
P19 position, and Tyr5 and Lys6 are in P29 and P39 positions,
respectively. The P29 residue Tyr5 maintains stacking interactions
with Phe188 of subtilisin (Fig. 4A, panel 1).
In domain 2 of CrSPI-1, Glu49 takes the position of His3 in the
P1 pocket of domain 1 and makes 8 (73%) of the 11 total hydrogen
bonding contacts with subtilisin. The remaining hydrogen bonding
contacts with subtilisin are from P19 Glu49, P29 Tyr50 and P4
Val45 of domain 2 (Table S2). Similar to the P29 residue Tyr5 of
domain 1, Tyr50 takes the P29 position in domain 2 and maintains
stacking interactions with Phe188 of subtilisin (Fig. 4A, panel 2).
The reactive site residues are well defined in the electron density
map (Fig. 4C). In addition, the P3 residue Cys46 mediates
hydrophobic interactions with the side chain of Leu125 of
subtilisin. Overall, the RSL interactions in domain 2 clearly
indicate that the P1 residue Glu48 is the primary mediator of the
interaction with subtilisin. These observations show that domain 1
may not be a strong inhibitor of subtilisin compared to domain 2.
Notably, domain 2 inhibits subtilisin with a Ki of 2.5 nM, whereas
CrSPI-1 domain 1 did not inhibit subtilisin [9]. However, the Ki
for full-length CrSPI-1 was 1.43 nM.
Rigidity of the RSL
The conformations adopted by the reactive site loops (RSLs) of
both domains of rCrSPI were similar and superimposable with an
rmsd of 0.80 A ˚ for the residues from positions P3 to P39 (Fig. 4B).
The RSLs in several families of serine protease inhibitors in many
complexes and in different crystal environments adopt similar
conformations (Fig. S2). Similar to other members of the Kazal
family of inhibitors, the disulfide bonds formed by cysteine
Figure 4. Interactions between CrSPI-1 domains and subtilisin. Stereo view of the interactions between subtilisin and the reactive site loops
(RSLs) of (A) (1)domain-1 (magenta) and (2) domain-2 (yellow). For subtilisin and for the CrSPI-1 domains same colors were used as in Fig. 1. (B)
Superimposition of the reactive site loops of both domains. (C) Electron density maps. (1) Stereo view of the final 2Fo-Fc map for the reactive site loop
(RSL) region of domain-1 and (2) domain-2 of CrSPI-1 bound to subtilisin. These maps are contoured at a level of 1s. These figures were prepared by
using PyMol [54].
doi:10.1371/journal.pone.0018838.g004
Structure of CrSPI: Subtilisin Complex
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18838residues at the P3 and P59 positions (Cys1 and Cys8 in domain 1
and Cys46 and Cys54 in domain 2) of CrSPI-1 may hold the RSL
in a relatively rigid conformation.
The backbone torsion angles (y/Q angles) of the RSLs of
CrSPI-1 were similar to each other and to other protease
inhibitors, such as OMTKY3 and Eglin-C complexed with
subtilisin (Table S3). In addition, the torsion angles of the RSL
backbones of CrSPI-1 were similar to several structurally
unrelated serine protease inhibitor complexes and confirm the
canonical binding mode for CrSPI-1 (Table S3).
Superimposition of the active site region of the subtilisin
complexes of OMTKY3 and Eglin C with the CrSPI-1: subtilisin
complex revealed that different inhibitor loop sequences can be
accommodated within the substrate binding site of subtilisin with
minimal side chain rearrangement (Fig. S2). Furthermore, it
indicates that the RSLs of these inhibitors have a rigid
conformation, which is supported by the fact that both main
chain and side chain groups of subtilisin remain in the same
relative conformation in several complexes and in the uncom-
plexed form. In domain 2, two out of three S-S bridges (Cys41-
Cys70 and Cys45-Cys64) are connected to the central a-helix
region and maintain a rigid conformation for the RSL of this
domain, unlike the RSL in domain 1. Notably, the presence of
three disulfide bonds in domain 2 explains the rigidity, specificity
and potency of this domain towards its particular cognate protease
subtilisin. It is worth mentioning here that in the case of
OMSVP3, engineering an additional disulfide bridge increased
the specificity for only one protease, a-chymotrypsin, and
decreased the specificity for other proteases [23].
In addition to the S-S bridges, there are three important
internal hydrogen bonding contacts that maintain the rigidity of
the RSLs in CrSPI-1. These contacts in domain 1 are (1) the P2-
P19 hydrogen bond between the carbonyl oxygen of Pro2 and
amide nitrogen of Thr4 of the reactive site loop, (2) the hydrogen
bond between Asn18 and Phe21, and (3) the interaction of N
d2 of
Asn18 with the main chain carbonyl atoms of Pro2 and Thr4 at
the P2 and P19 positions of the RSL. Similarly, in domain 2, the
interactions through the side chains of Asn62, Thr47 and Glu49
maintain the rigidity of the RSL. The interactions between Thr47
and Glu49 are similar to the interactions of P2-P19 of domain 1. In
order to reduce the entropic cost of binding, the RSLs of Kazal-
type inhibitors and of CrSPI-1 in particular are firmly held in a
preferred conformation that is complementary to the substrate-
binding site of specific proteases. A rigid conformation of the RSL
is thought to prevent proteolytic cleavage of the inhibitor upon
interaction with proteases [43].
In order to verify the hypothesis that the rigidity of the RSL
protects against the proteolytic cleavage by subtilisin, we
investigated the interaction of a peptide (VCTEEY) derived from
the RSL region of domain 2 of CrSPI-1 using Isothermal Titration
Calorimetric (ITC) experiments (Fig. 5). Titration with the
VCTEEY peptide did not resemble a hydrolytic process but a
proper binding event. Other peptides (e.g., CPHTYKPVCG and
LCPHTY) showed markedly different thermal profiles when
injected into subtilisin (very large, constant heats of reaction,
independent of the molar ratio), which could be indicative of a
hydrolytic process. Nevertheless, the titration of VCTEEY showed
saturation characteristics and was analyzed as a binding process
that exhibited an enthalpically driven event with an affinity (Ka)o f
2610
3 M
21 (Kd=500 mM) (Fig. 5). This indicates that the rigidity
of the RSL peptide is not the only factor that affects the proteolytic
cleavage of the inhibitor, but the sequence of the interacting
peptide might also be important for inhibition. The rigidity and
compactness of the domains of CrSPI-1 are due to the presence of
disulphide bridges. Hence no structural changes are anticipated
between native and recombinant forms. Moreover, recently we
have determined the structure of domain 1 (pdb code 3PIS) which
superimposed well with the CrSPI-1 domain 1 of the complex and
observed no conformational changes [57].
Discussion
Specificity of the CrSPI-1 domains
Kazal-type serine protease inhibitors are single or multi-domain
proteins with domains that usually have different specificities
towards a particular protease [44]. Although the sequence of the
RSL tends to be highly variable, the specificity of the overall
molecule for a protease is dictated by the P1 residue. His3 is the P1
residue in the RSL of domain 1, whereas Glu48 is the P1 residue in
the RSL of domain 2. Several Kazal-type inhibitors with Glu in the
P1 site are known to inhibit subtilisin. For instance, the five-domain
Figure 5. Calorimetric titration for peptide VCTEEY binding to
Subtilisin at 376C. Each peak represents the injection of VCTEEY
11 mM into the calorimetric cell containing 0.063 mM Subtilisin in
buffer PBS pH 7.4, 10 mM BME. Injections of 2 mL of ligand solution
were performed. The experimental data were fitted considering a
model in which Subtilisin binds a single peptide molecule. Non-linear
regression analysis provided an association constant of 1.9610
3 M
21
and a binding enthalpy of 217.6 kcal/mol.
doi:10.1371/journal.pone.0018838.g005
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domains with P1 Glu residues [45], and EPI1, a Kazal-like
Protease Inhibitor from Phytophthora infestans [46], has Glu as the
P1 residue. Thus, the presence of Glu in the P1 position makes
the inhibitor more specific for subtilisin [45,47]. Glu49 is buried
in the S1 pocket with 8 hydrogen bonding contacts with subtilisin
compared to His3, the P1 residue of domain 1, which makes only
five hydrogen bonding contacts. This suggests that Glu49 in the
P1 pocket of domain 2 is more specific and maintains a tight
interaction with subtilisin. The RSL residues of domains 1 and 2
contribute 445 A ˚ 2 and 530 A ˚ 2 of buried surface area, respective-
ly, which accounts for approximately 76% and 90% of the
binding interfaces with subtilisin, respectively. Thus, the RSL of
domain 2 contributes a greater buried area compared to the RSL
of domain 1. Notably, domain 2 inhibits subtilisin with a Ki of
2.6 nM [9]. Furthermore, the ITC experiments on full-length
CrSPI-1 revealed the presence of two non-identical binding sites;
each domain binds one subtilisin molecule. These results suggest
Figure 6. Model of Furin-CrSPI-Subtilisin heterotrimer complex. A schematic illustration on how CrSPI elicits a dual-inhibitory activity to
regulate serine protease-driven antimicrobial response during acute phase innate immune response while maintaining homeostasis under naı ¨ve
condition. Essentially, CrSPI employs its domain 1 (purple) to targets host’s serine proteases (e.g. Furin, in brown) and its domain 2 (yellow) to target
the microbial serine proteases (e.g. Subtilisin A in blue) to elicit this dual-inhibitory and regulatory mechanism.
doi:10.1371/journal.pone.0018838.g006
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molecule first, and then domain 1 binds a second subtilisin at a
slightly lower affinity.
CrFurin and CrSPI-1
Previously we have shown the inhibition of CrFurin by CrSPI-1
in an ex-vivo inhibition assay [9]. However the precise mechanism
of this inhibition is not yet established. CrFurin, a homolog of
subtilisin, shows specificity towards paired basic residues for
cleavage [48]. Furin cleaves a wide range of proproteins at the
consensus sequence Arg-Xaa-Lys/Arg-Arg- Q, and the minimal
consensus sequence for Furin is Arg-Xaa-Xaa-Arg- Q. Although
neither of the two domains of CrSPI-1 contains this consensus
sequence, the domain 1 RSL consists of two basic residues (His3
and Lys6). Notably, Kazal-type inhibitors recognize proteases in a
substrate-like manner. Furin might not cleave this RSL due to its
rigid conformation and the presence of basic residues probably
renders it as a substrate-like inhibitor. Several proteins have been
engineered to contain a Furin consensus motif in their reactive site
loops to thereby inhibit Furin. For instance, mutation of the turkey
ovomucoid third domain RSL sequence from Ala-Cys-Thr-Leu18
to Arg-Cys-Lys-Arg18 or mutation of the a1-antitrypsin Portland
RSL from Ala355-Ile-Pro-Met358 to Arg355-Ile-Pro-Arg358 both
produced effective inhibitors for Furin [49]. These inhibitors
mimic highly specific substrates. Due to the tight binding and
specific rigid conformation of the RSL residues, these inhibitors
are able to arrest the enzymatic reaction at the intermediate stage
of hydrolysis of the peptide bond [50].
Model of the domain 1 CrSPI-1: Furin complex
Furin is a subtilisin-related serine protease, and a member of
the proprotein convertase family. Although, subtilisin is obtained
from bacteria belonging to the Bacillus species, Furin is considered
as a eukaryotic version of subtilisin, which is ubiquitously
expressed [48,51253]. The Furin binding mode of CrSPI-1
was predicted based on the crystal structures of CrSPI-1:
subtilisin and human Furin (Pdb code 1P8J). The host Furin is
a homolog of the bacterial subtilisin, and these serine proteases
share a sequence identity of 23% (,40% similarity). Moreover,
the structure of subtilisin superimposes on the subtilisin-like
domain of Furin with an rmsd of 2 A ˚ for 268 Ca atoms of 274
Ca atoms of subtilisin. The domain 1 CrSPI-1: subtilisin complex
was superimposed onto the structure of Furin (pdb code 1P8J),
and the coordinates of CrSPI-1 were copied to Furin to generate
the CrSPI-1:Furin complex model (Figs. 6, S4 and S5). The RSL
region from P3 (Cys1) to P39 (Lys6) occupies the substrate
binding site of human Furin. This is expected as Furins and
subtilisins have highly homologous structures. However, this
needs to be experimentally verified. Based on our analysis, we
speculate that domain 1 of CrSPI-1 is responsible for the
inhibition of CrFurin. Moreover domain 2 is shown to be an
inhibitor of Subtilisin [9]. It is possible that the two domains of
CrSPI-1 are products of a gene duplication event that generated
a dual specificity inhibitor with one of the domains functioning as
an inhibitor of host proprotein-converting subtilisin-like enzyme,
CrFurin, and another domain functioning as a pathogen-specific
protease (subtilisin) inhibitor.
Possible immunomodulatory activities of CrSPI-1
The preference of CrSPI-1 domain 2 for the microbial protease
subtilisin suggests that this isoform targets serine proteases of
invading microbes. In fact, subtilisin is the virulence factor used
by the pathogen to gain entry into host cells during an infection.
Besides direct suppression of the microbial proteases, CrSPI-1 has
been shown to target the host’s endogenous proteases like the
CrFurin. This is supported by the observation that in response to
an infection, a dynamic reciprocal expression profile of the
CrSPI-1 and CrFurin transcripts was observed [9]. CrSPI-1 has
been proposed to regulate the serine protease-driven antimicro-
bial defense during the acute phase of infection while maintaining
homeostasis under normal physiological conditions [9]. It has also
been found to interact with microbial subtilisins as well as an
endogenous C3 complement from the host, which is required for
the clearance of pathogens. It is possible that CrSPI-1 serves an
immunomodulatory function by interacting with host and
microbial proteases through its independent domains (Fig. 6).
We hypothesize that the two domains of CrSPI-1 have different
substrate preferences. Domain 2 might be more potent and
specific towards the bacterial protease, subtilisin, whereas domain
1 likely interacts with the host protease Furin. The structure of
the CrSPI-1: subtilisin ternary complex is the first step towards an
understanding of the molecular perspective of the antibacterial
response while maintaining homeostasis for the host through such
a dual-inhibitory mechanism. The involvement of serine
proteases as the virulent factor in the entry of several microbial
pathogens makes it an important target for the treatment of
several infectious diseases.
Supporting Information
Figure S1 Alignment of amino acid sequences of non-classical
group I Kazal-type inhibitors AEI, CrSPI-1 domain I, domain II
and a selected classical Kazal-type inhibitor OMSVP3. The
sequences were aligned using CLUSTAL-W. The reactive site is
denoted with an arrow. Disulfide bonds are linked as follows: a-b,
II-IV, and III-VI for the non classical group I inhibitors and I-V,
II-IV, and III-VI for the classical inhibitors. In nonclassical group
II inhibitor family, there is an additional disulphide bridge
between a and b half cystines.
(TIF)
Figure S2 Conformations of the reactive site loop (RSL).
Superimposition of the reactive site loops of domain-1 (magenta),
domain-2 (yellow), Eglin C (gray) and OMTKY3 (cyan). The
RSLs are shown in stick representation whereas the substrate
binding site of subtilisin is shown in surface representation. These
figures were generated by using PyMol.
(TIF)
Figure S3 Isothermal Titration Calorimetric (ITC) curve for
rCrSPI-1 titrated against subtilisin at 37uC. Each peak represents
the injection of rCrSPI-1 0.2 mM into the ITC cell containing
subtilisin 0.012 mM, in buffer PBS pH 7.4, 10 mM BME. A
sequence of 18 injections, each injection consisting of 2 mLo f
ligand solution, was performed. The experimental data were fitted
considering a model in which CrSPI-1 binds two Subtilisin
molecules, either employing a general model based on the overall
association parameters or considering two non-identical and





21 were obtained from
non-linear regression analysis, corresponding to dissociation
constants of 0.42 and 59 mM, respectively.
(TIF)
Figure S4 Ca trace for the heterotrimer Furin-CrSPI-Subtilisin
complex model. Furin and subtilisin share a sequence identity of
23%. The Furin:CrSPI-1 complex model was generated by
superimposing domain-1 CrSPI-1: subtilisin complex onto the
structure of Furin (pdb code 1p8j), which yielded an rmsd of 2A ˚ for
Structure of CrSPI: Subtilisin Complex
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Subtilisin heterotrimer complex was generated using the modeled
Furin-CrSPI-1-domain-1 and subtilisin-CrSPI-1-domain-2 complex
crystal structure.
(TIF)
Figure S5 Surface representation for Furin and Subtilisin, and
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